People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Other, Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| VerAvanti Inc. | — | Other | Series B | $28.9M | $149.5M | 2025 |
| RF Surgical Systems, Inc | — | Other Health Care | Series A | $14.6M | $2.4M | 2010 |
| Inventprise LLC | — | Biotechnology | Seed | $3.5M | $74.1M | 2021 |
David Goesling at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Goesling on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Frederic Moll | 1 | 10 |
| Josh Baltzell | 1 | 7 |
| David Auth | 1 | 5 |
| Doug Carlisle | 1 | 4 |
| Douglas Carlisle | 1 | 4 |
| Jeffrey Port | 1 | 4 |
| Gerald McMorrow | 1 | 3 |
| Michael Moyer | 1 | 2 |
| Juan Vegarra | 1 | 2 |
| Subhash Kapre | 1 | 2 |
| William Blair | 1 | 2 |
| Kevin Cosens | 1 | 1 |
| Eric Siebel | 1 | 1 |
| Luis Savastano | 1 | 1 |
| Russell Garrison | 1 | 1 |
| Pradip Ghate | 1 | 1 |
| Yves Leurquin | 1 | 1 |
| Doug Allen | 1 | 1 |
| James Fitzsimmons | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.